The firm will use the money to advance its lead FAP-targeting radioligand candidate into clinical development.

The firm will use the funds to conduct a Phase I/II trial of an adoptive cell therapy designed to activate T regulatory cells against cancer.

The firm is hoping to show that the RNAi drug can treat HoFH by reducing production of ANGPTL3, which regulates lipid and lipoprotein metabolism.

Data from a Phase I trial of Avmapki Fakzynja also supports the regimen's tolerability and suggests its potential activity in ...

Cero will use Invivoscribe's multiparametric flow cytometry assay to detect minimal residual disease in patients and evaluate the therapy's efficacy.

The organizations launched the center with a $20 million CZI grant to build on the success of the first personalized CRISPR base-editing therapy.

The Phase II trial will compare progression-free survival in lung cancer patients treated according to their molecular subtypes.

The trial will test the drug in metastatic castration-resistant prostate cancer patients with low alkaline phosphatase levels, a marker of less advanced disease.

The firm is launching a Phase II trial of its dendritic cell vaccine following promising preliminary efficacy and favorable safety results in Phase I.

Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...

The company and the German university hospital will initially focus on developing screening programs and precision therapies for heart diseases.

The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...